


An R&D-based Pharmaceutical Company Taking on the Challenge of Creating Original and Innovative in Prescription Drugs

To realize our corporate philosophy, “Dedicated to the Fight against Disease and Pain,” we focus our finite management resources on drug discovery and development, creating innovative drugs, such as the cancer immunotherapy OPDIVO.

Feature 1


Continuing Vigorous Investment in Drug Development



R&D costs (FY2021)	R&D cost-to-revenue ratio (FY2021)
¥75.9 billion	21.0 %

Feature 2


R&D Capabilities Combining In-house Drug Discovery and Open Innovation



Number of joint research projects with universities, biopharmaceutical companies, etc. (As of end of March 2022)	Number of approvals obtained (FY2021)
About 200	7 approvals

Feature 3


A Pipeline that Continuously Markets New Drugs



Number of clinical trials conducted (FY2021)	Number of new products launched and additional indications approved (FY2017 to FY2021)
82 trials	31 products

Feature 4

High Profit Margins Making Investing in Growth Possible



Revenue (FY2021)	Operating income to revenue ratio (FY2021)
¥361.4 billion	28.6 %

Main Products

- ONCOLOGY**
 - **OPDIVO Intravenous Infusion** for the Treatment of Malignant Tumors
 - **KYPROLIS for Intravenous Injection** for the Treatment of Malignant Tumors
 - **EMEND Capsules / PROEMEND for Intravenous Injection** for the Treatment of Chemotherapy-induced Nausea and Vomiting
 - **DEMSEER Capsules** for the Improvement of Status of Catecholamine Excess Secretion in Pheochromocytoma
 - **BRAFTOVI Capsules** and **MEKTOVI Tablets** for the Treatment of Malignant Tumors
 - **VELEXBRU Tablets** for the Treatment of Malignant Tumors
 - **ADLUMIZ Tablets** for the Treatment of Cancer Cachexia
- DIABETES**
 - **GLACTIV Tablets** for the Treatment of Type 2 Diabetes
 - **FORXIGA Tablets** for the Treatment of Diabetes (Also approved for indications for chronic heart failure and chronic kidney disease)
- CARDIOVASCULAR DISEASE**
 - **ONOACT for Intravenous Infusion** for the Treatment of Tachyarrhythmia
 - **OPALMON Tablets** for the Treatment of Peripheral Circulatory Disorder
 - **CORALAN Tablets** for the Treatment of Chronic Heart Failure
- IMMUNE SYSTEM DISEASE**
 - **ORENCIA for Subcutaneous Injection** for the Treatment of Rheumatoid Arthritis
- NEUROLOGICAL DISEASE**
 - **RIVASTACH Patch** for the Treatment of Alzheimer’s Disease
 - **ONGENTYS Tablets** for the Treatment of Parkinson’s Disease
- Others**
 - **PARSABIV Intravenous Infusion for Dialysis** for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis
 - **STAYBLA Tablets** for the Treatment of Overactive Bladder (OAB)
 - **RECALBON Tablets** for the Treatment of Osteoporosis
 - **ONON Capsules** and **ONON Dry Syrup** for the Treatment of Bronchial Asthma and Allergic Rhinitis
 - **JOYCLU Intra-articular Injection** for the Improvement of Joint Function

Sales of Main Products in FY2021

OPDIVO Intravenous Infusion	¥112.4 billion	ONOACT for Intravenous Infusion	¥4.9 billion
FORXIGA Tablets	¥36.7 billion	OPALMON Tablets	¥4.7 billion
GLACTIV Tablets	¥24.5 billion	ONON Capsules	¥3.6 billion
ORENCIA for Subcutaneous Injection	¥22.9 billion	ONGENTYS Tablets	¥2.9 billion
PARSABIV Intravenous Infusion for Dialysis	¥8.9 billion	RIVASTACH Patch	¥2.9 billion
KYPROLIS for Intravenous Injection	¥8.4 billion	BRAFTOVI Capsules	¥2.7 billion
VELEXBRU Tablets	¥6.3 billion	MEKTOVI Tablets	¥2.2 billion

Note: Revenue based on purchase price (shipment price)